These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33070375)

  • 21. Elastographic ultrasound: an additional image tool in Sjögren's syndrome.
    Kimura-Hayama E; Criales-Vera S; Azpeitia-Espinosa L; Pacheco-Molina C; Reyes E; Lima G; Hernandez-Ramirez D; Llorente L; Hernandez-Molina G
    Int J Rheum Dis; 2018 Jun; 21(6):1293-1300. PubMed ID: 29624878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study.
    Streckfus C; Bigler L; Navazesh M; Al-Hashimi I
    Clin Oral Investig; 2001 Jun; 5(2):133-5. PubMed ID: 11480812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible role for IL-40 and IL-40-producing cells in the lymphocytic infiltrated salivary glands of patients with primary Sjögren's syndrome.
    Guggino G; Rizzo C; Mohammadnezhad L; Lo Pizzo M; Lentini VL; Di Liberto D; La Barbera L; Raimondo S; Shekarkar Azgomi M; Urzì O; Berardicurti O; Campisi G; Alessandro R; Giacomelli R; Dieli F; Ciccia F
    RMD Open; 2023 May; 9(2):. PubMed ID: 37137540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Artificial neural networks help to identify disease subsets and to predict lymphoma in primary Sjögren's syndrome.
    Baldini C; Ferro F; Luciano N; Bombardieri S; Grossi E
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):137-144. PubMed ID: 30156549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phagocyte-specific S100A8/A9 is upregulated in primary Sjögren's syndrome and triggers the secretion of pro-inflammatory cytokines in vitro.
    Nicaise C; Weichselbaum L; Schandene L; Gangji V; Dehavay F; Bouchat J; Balau B; Vogl T; Soyfoo MS
    Clin Exp Rheumatol; 2017; 35(1):129-136. PubMed ID: 27749214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum levels of interleukin-34 and clinical correlation in patients with primary Sjögren's syndrome.
    Liu Y; Zhang B; Lei Y; Xia L; Lu J; Shen H
    Int J Rheum Dis; 2020 Mar; 23(3):374-380. PubMed ID: 31823505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progenitor cell niche senescence reflects pathology of the parotid salivary gland in primary Sjögren's syndrome.
    Wang X; Bootsma H; Terpstra J; Vissink A; van der Vegt B; Spijkervet FKL; Kroese FGM; Pringle S
    Rheumatology (Oxford); 2020 Oct; 59(10):3003-3013. PubMed ID: 32159757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome.
    Awada A; Nicaise C; Ena S; Schandéné L; Rasschaert J; Popescu I; Gangji V; Soyfoo MS
    Ann Rheum Dis; 2014 Jun; 73(6):1259-63. PubMed ID: 24385203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin D in "early" primary Sjögren's syndrome: does it play a role in influencing disease phenotypes?
    Baldini C; Delle Sedie A; Luciano N; Pepe P; Ferro F; Talarico R; Tani C; Mosca M
    Rheumatol Int; 2014 Aug; 34(8):1159-64. PubMed ID: 24097207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of fractalkine in the pathogenesis of primary Sjögren syndrome: increased serum levels of fractalkine, its expression in labial salivary glands, and the association with clinical manifestations.
    Lee JH; Kwok SK; Jung SM; Lee J; Lee JS; Baek SY; Kim EK; Ju JH; Park SH; Kim HY
    J Rheumatol; 2014 Dec; 41(12):2425-38. PubMed ID: 25320221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The IL33/ST2 axis in Sjogren syndrome in relation to disease activity.
    Margiotta DP; Navarini L; Vadacca M; Lo Vullo M; Pignataro F; Basta F; Afeltra A
    Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1295-9. PubMed ID: 27097949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What exactly is the relationship between plasma cytokines and the clinical phenotype of primary sjögren's syndrome? a single-centre retrospective study.
    Shang L; He L; Li M
    Int Immunopharmacol; 2023 Sep; 122():110567. PubMed ID: 37418983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased CD4
    Wang S; Shen H; Bai B; Wu J; Wang J
    J Immunol Res; 2021; 2021():6658324. PubMed ID: 34095321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-14α as a Putative Biomarker for Stratification of Dry Eye in Primary Sjögren's Syndrome.
    Liang Y; Xian Z; Fu D; Liu S; Yao Y; Jin Y; Gao C; Shen L; Shi G; He J
    Front Immunol; 2021; 12():673658. PubMed ID: 34012457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-β inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjögren's syndrome.
    Benchabane S; Belkhelfa M; Belguendouz H; Zidi S; Boudjelida A; Youinou P; Touil-Boukoffa C
    Inflammopharmacology; 2018 Oct; 26(5):1165-1174. PubMed ID: 29869303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of interleukin-17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta-analysis.
    Zhang LW; Zhou PR; Wei P; Cong X; Wu LL; Hua H
    Scand J Immunol; 2018 Apr; 87(4):e12649. PubMed ID: 29476557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma.
    Baldini C; Mosca M; Della Rossa A; Pepe P; Notarstefano C; Ferro F; Luciano N; Talarico R; Tani C; Tavoni AG; Bombardieri S
    Clin Exp Rheumatol; 2013; 31(2):272-80. PubMed ID: 23343785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implications of long-term medication of oral steroids and antimalarial drugs in primary Sjögren's syndrome.
    Reksten TR; Brokstad KA; Jonsson R; Brun JG; Jonsson MV
    Int Immunopharmacol; 2011 Dec; 11(12):2125-9. PubMed ID: 21964047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome.
    Hargreaves P; Daoudlarian D; Theron M; Kolb FA; Manchester Young M; Reis B; Tiaden A; Bannert B; Kyburz D; Manigold T
    Arthritis Res Ther; 2019 Jul; 21(1):175. PubMed ID: 31319889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development.
    Goules AV; Argyropoulou OD; Pezoulas VC; Chatzis L; Critselis E; Gandolfo S; Ferro F; Binutti M; Donati V; Zandonella Callegher S; Venetsanopoulou A; Zampeli E; Mavrommati M; Voulgari PV; Exarchos T; Mavragani CP; Baldini C; Skopouli FN; Fotiadis DI; De Vita S; Moutsopoulos HM; Tzioufas AG
    Front Immunol; 2020; 11():594096. PubMed ID: 33193443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.